[1]
|
Olefsky, J.M. (2000) Treatment of insulin resistance with pe-roxisome proliferators-activated receptor γ agonists. Journal of Clinical Investigation, 106, 467-472.
doi:10.1172/JCI10843
|
[2]
|
Smith, U. (2002) Thiazolidinedi-one-induced effects beyond glycemic control. British Journal of Diabetes & Vascular Disease, 2, S24-S27.
|
[3]
|
Walczak, R. and Tontonoz, P. (2002) PPRadigms and PPARadoxes: Expanding roles for PPAR-gamma in the control of lipid metabolism. Journal of Lipid Research, 43, 177-186.
|
[4]
|
Kersten, S. (2008) Peroxisome proliferator activated receptors and lipo-protein metabolism. PPAR Research, 2008, 132960. doi:10.1155/2008/132960
|
[5]
|
Goldberg, R.B., Kendall, D.M., Deeg, M.A., Buse, J.B., Zagar, A.J., Pinaire, J.A. Tan, M.H., Khan, M.A., Perez, A.T. and Jacober, S.J. (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 28, 1547-1554.
doi:10.2337/diacare.28.7.1547
|
[6]
|
Van Wijk, J.P.H., De Koning, E.D.P., Martens, E.P. and Rabelink, T.J. (2003) Thiazolidinediones and blood lipids in type 2 diabetes. Arteri-osclerosis, Thrombosis, and Vas- cular Biology, 23, 1744-1749.
doi:10.1161/01.ATV.0000090521.25968.4D
|
[7]
|
Lee, C., Ol-son, P. and Evans, R.M. (2003) Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferators-activated receptors. Endocrinology, 144, 2201- 2207. doi:10.1210/en.2003-0288
|
[8]
|
Wolf, G. (2004) Tissue-specific knockout defines peroxisome proliferators-activated receptor gamma function in muscle and liver. Nutrition Reviews, 62, 253-255.
doi:10.1301/nr2004.jun253-255
|
[9]
|
Glass, C.K. (2001) Potential roles of the peroxisome proliferator-activated receptorγ in macrophage biology and atherosclerosis. Journal of Endo-crinology, 169, 461-464. doi:10.1677/joe.0.1690461
|
[10]
|
Galetto, R., Albajar, M., Polanco, J.I., Zakin, M.M., Rodriguez-Rey, J.C. (2001) Identification of a peroxisome proliferator-activated receptor response element in the apolipoprotein E gene control region. Biochemical Journal, 357, 521-527. doi:10.1042/0264-6021:3570521
|
[11]
|
Mak, P.A., Laffitte, B.A., Desrumaux, C., Joseph, S.B., Curtiss, L.K., Mangelsdorf, D.J., Tontonoz, P. and Edwards, P.A. (2002) Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. Journal of Biological Chemistry, 277, 31900-31908. doi:10.1074/jbc.M202993200
|
[12]
|
Willson, T.M., Cobb, J.E., Cowan, D.J., Wiethe, R.W., Correa, I.D., Prakesh, S.R., Beck, K.D., Moore, L.B., Kliewer, S.A. and Lehmann, J.M. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor-γ agonism and the antihyperglycemic activity of thiazolidinediones. Journal of Medicinal Chemistry, 39, 665-668. doi:10.1021/jm950395a
|
[13]
|
Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔC T method. Methods, 25, 402-408.
doi:10.1006/meth.2001.1262
|
[14]
|
Jackson, R.L., Sparrow, J.T., Baker, H.N., Morrisett, J.D., Taunton, O.D. and Gotto, A.M. Jr. (1974) The primary structure of apolipoprotein-serine. Journal of Biological Chemistry, 249, 5308-5313.
|
[15]
|
Laffitte, B.A., Joseph, S.B., Walczak, R., Pei, L., Wilpitz, D.C., Collins, J.L. and Tontonoz, P. (2001) Autoregulation of the human liver X receptor α promoter. Molecular and Cellular Biology, 21, 7558-7568.
doi:10.1128/MCB.21.22.7558-7568.2001
|
[16]
|
Goldberg, I.J. (2001) Diabetic dyslipidemia: Causes and consequences. Journal of Clinical Endocrinology & Metabolism, 86, 965-971. doi:10.1210/jc.86.3.965
|
[17]
|
Yue, L. and Mazzone, T. (2009) Peroxisome proliferator-activated receptor-γ stimulation of adipocyte apoE gene transcription mediated by the liver receptor X pathway. Journal of Biological Chemistry, 284, 10453-10461.
doi:10.1074/jbc.M808482200
|
[18]
|
Berbee, J.F.P., Van der Hoogt, C.C., Sundararaman, D., Havekes, L.M. and Rensen, P.C.N. (2005) Severe hypertriglyceridemia in human apoC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. Journal of Lipid Research, 46, 297-306. doi:10.1194/jlr.M400301-JLR200
|
[19]
|
Malik, S. (2003) Transcriptional regulation of the apolipoprotein AI gene. Frontiers in Bioscience, 8, 360-368.
doi:10.2741/1005
|
[20]
|
Staels, B. and Auwerx, J. (1998) Regulation of apoA-I gene expression by fibrates. Atherosclerosis, 137, S19- S23. doi:10.1016/S0021-9150(97)00313-4
|
[21]
|
Qin, S., Liu, T., Kamanna, A.S. and Kashyap, M.L. (2007) Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 2428- 2434. doi:10.1161/ATVBAHA.107.150193
|
[22]
|
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R., Nicol, C.J., Vinson, C., Gonzales, F.J. and Reitman, M.L. (2003) Liver peroxisome proliferator-activated receptor-γ con-tributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. Journal of Biological Chemistry, 278, 34268-34276.
doi:10.1074/jbc.M300043200
|